<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Rivastigmine for vascular cognitive impairment - Birks, J - 2013 | Cochrane Library</title> <meta content="Rivastigmine for vascular cognitive impairment - Birks, J - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004744.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Rivastigmine for vascular cognitive impairment - Birks, J - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004744.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD004744.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Rivastigmine for vascular cognitive impairment" name="citation_title"/> <meta content="Jacqueline Birks" name="citation_author"/> <meta content="University of Oxford" name="citation_author_institution"/> <meta content="jacqueline.birks@csm.ox.ac.uk" name="citation_author_email"/> <meta content="Bernadette McGuinness" name="citation_author"/> <meta content="National University of Ireland" name="citation_author_institution"/> <meta content="David Craig" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD004744.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/05/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004744.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004744.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004744.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Cholinesterase Inhibitors [*therapeutic use]; Dementia, Vascular [*drug therapy]; Nootropic Agents [*therapeutic use]; Phenylcarbamates [*therapeutic use]; Rivastigmine" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD004744.pub3&amp;doi=10.1002/14651858.CD004744.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="OeRCveEI";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD004744\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD004744\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD004744.pub3",title:"Rivastigmine for vascular cognitive impairment",firstPublishedDate:"May 31, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Dementia and Cognitive Improvement Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=OeRCveEI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004744.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004744.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD004744.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD004744.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004744.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD004744.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD004744.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD004744.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD004744.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD004744.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1946 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD004744.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#CD004744-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#CD004744-sec-0072"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#CD004744-sec-0015"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#CD004744-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#CD004744-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#CD004744-sec-0030"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/full#CD004744-sec-0071"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/appendices#CD004744-sec-0077"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/table_n/CD004744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/table_n/CD004744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Rivastigmine for vascular cognitive impairment</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information#CD004744-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jacqueline Birks</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information#CD004744-cr-0003">Bernadette McGuinness</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information#CD004744-cr-0004">David Craig</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information/en#CD004744-sec-0083">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 May 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD004744.pub3">https://doi.org/10.1002/14651858.CD004744.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD004744-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004744-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004744-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004744-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD004744-abs-0001" lang="en"> <section id="CD004744-sec-0001"> <h3 class="title" id="CD004744-sec-0001">Background</h3> <p>Vascular dementia represents the second most common type of dementia after Alzheimer's disease. In older patients, in particular, the combination of vascular dementia and Alzheimer's disease is common, and is referred to as mixed dementia. The classification of vascular dementia broadly follows three clinico‐pathological processes: multi‐infarct dementia, single strategic infarct dementia and subcortical dementia. Not all victims fulfil strict criteria for dementia and may be significantly cognitively impaired without memory loss, when the term vascular cognitive impairment (VCI) is more useful. Currently, no established standard treatment for VCI exists. Reductions in acetylcholine and acetyltransferase activity are common to both Alzheimer's disease and VCI, raising the possibility that cholinesterase inhibitors ‐ such as rivastigmine ‐ which are beneficial in Alzheimer's disease, may also be beneficial for VCI. </p> </section> <section id="CD004744-sec-0002"> <h3 class="title" id="CD004744-sec-0002">Objectives</h3> <p>To assess the efficacy of rivastigmine compared with placebo in the treatment of people with vascular cognitive impairment (VCI), vascular dementia or mixed dementia. </p> </section> <section id="CD004744-sec-0003"> <h3 class="title" id="CD004744-sec-0003">Search methods</h3> <p>We searched ALOIS (the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register) on 12 February 2013 using the terms: rivastigmine, exelon, "SDZ ENA 713". ALOIS contains records of clinical trials identified from monthly searches of a number of major healthcare databases (<i>The Cochrane Library</i>, MEDLINE, EMBASE, CINAHL, PsycINFO, LILACS), numerous trial registries and grey literature sources. </p> </section> <section id="CD004744-sec-0004"> <h3 class="title" id="CD004744-sec-0004">Selection criteria</h3> <p>All unconfounded randomized double‐blind trials comparing rivastigmine with placebo in the treatment of people with VCI, vascular dementia or mixed dementia were eligible for inclusion. </p> </section> <section id="CD004744-sec-0005"> <h3 class="title" id="CD004744-sec-0005">Data collection and analysis</h3> <p>Two reviewers extracted and assessed data independently, and agreement was reached after discussion. They noted results concerning adverse effects. </p> </section> <section id="CD004744-sec-0006"> <h3 class="title" id="CD004744-sec-0006">Main results</h3> <p>Three trials, with a total of 800 participants, were identified for inclusion. The participants in one trial did not have dementia, while the other two studies included participants with dementia of different severities. The dose of rivastigmine was different in each study. No pooling of study results was attempted because of these differences between the studies. </p> <p>One trial included 40 participants with subcortical vascular dementia (age range 40 to 90 years) with a mean mini‐mental state examination (MMSE) score of 13.0 and 13.4 in the rivastigmine and placebo arms, respectively. Treatment over 26 weeks was limited to 3 mg rivastigmine twice daily, or placebo. No significant difference was found on any outcome measure relevant to cognition, neuropsychiatric symptoms, function or global rating, or in the number of withdrawals before the end of treatment. </p> <p>Another trial included 710 participants with vascular dementia, including subcortical and cortical forms (age range 50 to 85 years). Over 24 weeks, a mean dose of rivastigmine of 9.4 mg/day was achieved versus placebo. Baseline MMSE was identical for both groups, at 19.1. Statistically significant advantage in cognitive response (but not with global impression of change or non‐cognitive measures) was seen with rivastigmine treatment at 24 weeks (MMSE change from baseline MD 0.6, 95% CI 0.11 to 1.09, P value 0.02; Vascular Dementia Assessment Scale (VaDAS) change from baseline MD ‐1.3, 95% CI‐2.62 to 0.02, P value 0.05 ). Significantly higher rates of vomiting, nausea, diarrhoea and anorexia and withdrawals from treatment were noted in the participants randomized to rivastigmine compared with placebo (withdrawals rivastigmine 90/365, placebo 48/345, OR 2.02, 95% CI 1.38 to 2.98) (withdrawals due to an adverse event rivastigmine 49/365, placebo 19/345, OR 2.66, 95% CI 1.53 to 4.62, P value 0.0005). </p> <p>The third study included 50 participants (age range 48 to 84 years) with mean MMSE scores of 23.7 and 23.9 in the rivastigmine and placebo arms, respectively. Over a 24‐week period, participants labelled as having cognitive impairment but no dementia (CIND) following ischaemic stroke were given up to 4.5 mg rivastigmine twice daily, or placebo. Primary and secondary outcome measures showed no statistically significant difference when considering neurocognitive abilities, function, neuropsychiatric symptoms and global performance. One participant in the rivastigmine group and two in the placebo group discontinued their medication because of an adverse effect. </p> </section> <section id="CD004744-sec-0007"> <h3 class="title" id="CD004744-sec-0007">Authors' conclusions</h3> <p>There is some evidence of benefit of rivastigmine in VCI from trial data from three studies. However, this conclusion is based on one large study. Rivastigmine is capable of inducing side effects that lead to withdrawal in a significant proportion of patients. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD004744-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD004744-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD004744-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fr#CD004744-abs-0004">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD004744-abs-0003" lang="en"> <h3>Rivastigmine for vascular cognitive impairment</h3> <p>Vascular dementia (i.e. dementia caused by disease of blood vessels affecting the supply of blood to the brain) is one of the most common types of dementia. It includes dementia caused by stroke. It may exist by itself or with other common dementias such as Alzheimer's disease. Sometimes vascular disease can present with cognitive problems which are less severe than dementia. Those with vascular dementia may have significant cognitive impairment without major memory loss. The term vascular cognitive impairment (VCI) is useful, because of the range of different ways in which people are affected. Rivastigmine is a drug widely used in Alzheimer's disease (AD). It works by preventing breakdown of acetylcholine, a neurotransmitter (signalling molecule). Levels of acetylcholine are reduced in VCI as well as in AD and so it may also help people with VCI. Researchers searched for all trials that compared rivastigmine with placebo in people with VCI, and identified three. Only one of these showed any significant results, and it did show some benefit for people with VCI who took rivastigmine. However, nausea and vomiting were a frequent side effect of taking the drug. Therefore it remains uncertain how useful rivastigmine is for people with VCI . </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD004744-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD004744-sec-0072"></div> <h3 class="title" id="CD004744-sec-0073">Implications for practice</h3> <section id="CD004744-sec-0073"> <p>Only one placebo‐controlled, double‐blind randomized trial has been conducted that was large enough to detect a clinically significant effect for rivastigmine compared with placebo for important outcomes in vascular dementia or vascular cognitive impairment. This trial demonstrated a positive effect of rivastigmine on cognition, but not on other important outcomes. </p> </section> <h3 class="title" id="CD004744-sec-0074">Implications for research</h3> <section id="CD004744-sec-0074"> <p>There is a theoretical basis for believing that rivastigmine may be beneficial in vascular cognitive impairment, but there are limited trial resources that have explored this in depth. Such trials are needed, and accurate trial design depends on further research into the aetiological mechanisms of vascular cognitive impairment, separation of subtypes and knowledge of their natural history, and better clarification of the role of other pharmacological methods of reducing neurovascular morbidity in general. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD004744-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD004744-sec-0015"></div> <p>As the older population increases, the number of dementia sufferers increases proportionally. Vascular dementia represents the second most common subtype of dementia and may exist in 'pure' form or 'mixed' with Alzheimer's disease or other common dementias. As not all of those affected fulfil strict criteria for dementia, and may be significantly cognitively impaired without memory loss, the term vascular cognitive impairment (VCI) is useful. </p> <p>Several forms of vascular damage can lead to cognitive impairment. Traditional concepts based on stroke and multi‐infarct dementia are limited, as VCI can arise from a broad range of pathologies. Mixed vascular dementia with Alzheimer's disease is the commonest form of VCI (<a href="./references#CD004744-bbs2-0026" title="Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late‐onset dementia in a multicentre, community‐based population in England and Wales. The Lancet2001;357:169‐75. ">MRC CFAS 2001</a>). Vascular dementia and Alzheimer's disease share risk factors (<a href="./references#CD004744-bbs2-0004" title="BlackSE . Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management. The journal of the Royal College of Physicians of Edinburgh2011;41(1):49‐56. [PUBMED: 21365068] ">Black 2011</a>), some histopathological changes (<a href="./references#CD004744-bbs2-0028" title="O'BrienJT , ErkinjunttiT , ReisbergB , RomanG , SawadaT , PantoniL , et al. Vascular cognitive impairment. The Lancet Neurology2003;2:89‐98. ">O'Brien 2003</a>), and may even represent different subtypes of the same entity (<a href="./references#CD004744-bbs2-0006" title="BullockR . Cholinesterase inhibitors and vascular dementia: another string to their bow?. CNS Drugs2004;18(2):79‐92. ">Bullock 2004</a>). </p> <p>In the absence of Alzheimer's disease, VCI may result from large cortical infarcts (death of brain tissue caused by a blocked artery) or more subtle white matter ischaemia (lack of oxygen) (<a href="./references#CD004744-bbs2-0028" title="O'BrienJT , ErkinjunttiT , ReisbergB , RomanG , SawadaT , PantoniL , et al. Vascular cognitive impairment. The Lancet Neurology2003;2:89‐98. ">O'Brien 2003</a>). Between these extremes lie small infarcts or lacunae. The clinical presentation varies according to the location and nature of the neuropathology (damage to the brain): single strategic infarcts present abruptly, while the onset of symptoms and signs due to subcortical damage from lacunae or white matter disease may be more insidious. Memory impairment is usually mild, and patients characteristically present with abnormalities in attention and executive functioning. The underlying damage is often to the neuronal circuitry of the prefrontal region rather than of the mesial temporal lobe (<a href="./references#CD004744-bbs2-0009" title="CummingsJL . Frontal‐subcortical circuits and human behavior. Archives of Neurology1993;50(8):873‐80. ">Cummings 1993</a>; <a href="./references#CD004744-bbs2-0012" title="ErkinjunttiT , InzitariD , PantoniL , WallinA , ScheltensP , RockwoodK , et al. Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission2000;59(Suppl):23‐30. ">Erkinjuntti 2000</a>). Non‐cognitive features such as depression, apathy and emotional lability may also be prominent (<a href="./references#CD004744-bbs2-0027" title="O'BrienJ , PerryR , BarberR , GholkarA , ThomasA . The association between white matter lesions on magnetic resonance imaging and noncognitive symptoms. Annals of the New York Academy of Sciences2000;903:482‐9. ">O'Brien 2000</a>). Physical impairment such as gait disorder or imbalance may be a concomitant feature (<a href="./references#CD004744-bbs2-0030" title="PohjasvaaraT , MantylaR , YlikoskiR , KasteM , ErkinjunttiT . Clinical features of MRI‐defined subcortical vascular disease. Alzheimer Disease and Associated Disorders2003;17(4):236‐42. ">Pohjasvaara 2003</a>). Radiological changes associated with VCI are common, most obviously following an overt event such as stroke, but also silently in a majority of the older population (up to 95% demonstrate white matter ischaemia, or small lacunar defects (<a href="./references#CD004744-bbs2-0004" title="BlackSE . Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management. The journal of the Royal College of Physicians of Edinburgh2011;41(1):49‐56. [PUBMED: 21365068] ">Black 2011</a>)). </p> <p>Currently, there is no established standard treatment for VCI, so clinicians must extrapolate from large primary and secondary prevention trials in ischaemic heart disease, hypertension and stroke. Cholinesterase inhibitors effectively improve a broad range of symptoms in some patients with Alzheimer's disease through enhancement of cholinergic neurotransmission. Reductions in acetylcholine and acetyltransferase activity are common to both Alzheimer's disease and VCI, raising the possibility that these drugs may also be beneficial for the latter (<a href="./references#CD004744-bbs2-0029" title="PerryE , KayDW . Some developments in brain ageing and dementia. British Journal of Biomedical Science1997;54(3):201‐15. ">Perry 1997</a>; <a href="./references#CD004744-bbs2-0035" title="ToghiH , AbeT , KimuraM , SahekiM , TakahashiS . Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarcts types as compared with Alzheimer‐type dementia. Journal of Neural Transmission1996;103:1211‐20. ">Toghi 1996</a>). </p> <p>The three internationally‐established cholinesterase inhibitors for the treatment of Alzheimer's disease are donepezil, rivastigmine and galantamine. Methodologically robust, placebo‐controlled trials involving large numbers of participants have demonstrated clear cognitive benefit in Alzheimer's disease with each drug (<a href="./references#CD004744-bbs2-0016" title="HansenRA , GartlehnerG , WebbAP , MorganLC , MooreCG , JonasDE . Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta‐analysis. Clinical Interventions in Aging2008;3(2):211‐25. [PUBMED: 18686744] ">Hansen 2008</a>). Additional gain has also been demonstrated in other areas, such as activities of daily living, global functioning and neuropsychiatric symptoms. The efficacy of cholinesterase inhibitors in VCI is less clear. A Cochrane review of the role of donepezil in VCI noted improvements in cognitive function and activities of daily living as well as more global measures of change (<a href="./references#CD004744-bbs2-0021" title="MaloufR , BirksJ . Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews2004, Issue 1. [DOI: 10.1002/14651858.CD004395.pub2] ">Malouf 2004</a>). </p> <p>Rivastigmine is a 'pseudo‐irreversible' inhibitor of acetylcholinesterase (AChE) and butyryl‐cholinesterase (BuChE). The additional inhibition of BuChE may be relevant in VCI, as rivastigmine is reasoned to have particular activity in affected regions of the brain associated with executive dysfunction and reduced attention (<a href="./references#CD004744-bbs2-0024" title="MorettiR , TorreP , AntonelloRM , CazzatoG , GriggioS , UkmarM , et al. Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16‐month, comparative study. International Journal of Clinical Practice2004;58(4):346‐53. ">Moretti 2004</a>). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD004744-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD004744-sec-0016"></div> <p>To assess the efficacy of rivastigmine compared with placebo in the treatment of people with vascular cognitive impairment (VCI), vascular dementia (VaD) or mixed dementia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD004744-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD004744-sec-0017"></div> <section id="CD004744-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD004744-sec-0019"> <h4 class="title">Types of studies</h4> <p>All unconfounded, randomized, double‐blind trials involving participants with vascular dementia, VCI or mixed dementia in which treatment with rivastigmine was compared with placebo were eligible for inclusion. </p> </section> <section id="CD004744-sec-0020"> <h4 class="title">Types of participants</h4> <p>Patients diagnosed as having VCI, dementia or mixed dementia on a basis of standardized diagnostic criteria such as the ADDTC (California State Alzheimer's disease Diagnostic and Treatment Center) (<a href="./references#CD004744-bbs2-0008" title="ChuiH , VictoroffJ , MargolinD , JagustW , ShankleR , KatzmanR . Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology1992;42(3 Part 1):473‐80. ">Chui 1992</a>), NINDS/AIREN (National Institute of Neurological Disorders and Stroke and the Association International pour la Recherche et l' Enseignement en Neurosciences) (<a href="./references#CD004744-bbs2-0032" title="RomanG , TatemichiT , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology1993;43(2):250‐60. ">Roman 1993</a>), and ICD‐10 (International Classification of Diseases of the World Health Organization) (<a href="./references#CD004744-bbs2-0037" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines. 10th Edition. Geneva: World Health organiazation, 1992. ">WHO 1992</a>), were eligible for inclusion. </p> <p>Diagnosis of VCI with no dementia was based on scores on cognitive impairment scales.</p> </section> <section id="CD004744-sec-0021"> <h4 class="title">Types of interventions</h4> <p>Rivastigmine at any dose compared with a parallel, placebo control group.</p> </section> <section id="CD004744-sec-0022"> <h4 class="title">Types of outcome measures</h4> <p>The review assessed the following outcomes:</p> <p> <ul id="CD004744-list-0001"> <li> <p>global impression (assessed by GDS, CDR‐SB, ADCS‐CGIC)</p> </li> <li> <p>functional performance (assessed by means of ADCS‐ADL, Chinese ADL)</p> </li> <li> <p>behavioural disturbance (assessed by NPI, GDS)</p> </li> <li> <p>cognitive function (assessed by means of ADAS‐Cog, VaDAS, MMSE, Chinese MMSE, FAS, TenPoint Clock Test, Color Trails 1, Color Trails 2) </p> </li> <li> <p>effect on carer</p> </li> <li> <p>death</p> </li> <li> <p>safety and adverse effects</p> </li> </ul> </p> </section> </section> <section id="CD004744-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD004744-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched ALOIS (<a href="http://www.medicine.ox.ac.uk/alois" target="_blank">www.medicine.ox.ac.uk/alois</a>) ‐ the Cochrane Dementia and Cognitive Improvement Group’s Specialized Register on 12 February 2013. The search terms used were: rivastigmine, exelon, "SDZ ENA 713". </p> <p>ALOIS is maintained by the Cochrane Dementia and Cognitive Improvement Group's Trials Search Co‐ordinator and contains studies in the areas of dementia prevention, dementia treatment and cognitive enhancement in healthy people. The studies are identified from:   </p> <p> <ol id="CD004744-list-0002"> <li> <p>Monthly searches of a number of major healthcare databases: MEDLINE, EMBASE, CINAHL, PsycINFO and LILACS. </p> </li> <li> <p>Monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the WHO portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others). </p> </li> <li> <p>Quarterly search of <i>The Cochrane Library</i>’s Central Register of Controlled Trials (CENTRAL). </p> </li> <li> <p>Six‐monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses; Australasian Digital Theses. </p> </li> </ol> </p> <p>To view a list of all sources searched for ALOIS see <a href="http://www.medicine.ox.ac.uk/alois/content/about-alois" target="_blank">About ALOIS</a> on the ALOIS website. </p> <p>Details of the search strategies used for the retrieval of reports of trials from the healthcare databases, CENTRAL and conference proceedings can be viewed in the ‘methods used in reviews’ section within the editorial information about the <a href="http://mrw.interscience.wiley.com/cochrane/clabout/articles/DEMENTIA/frame.html" target="_blank">Dementia and Cognitive Improvement Group</a>. </p> <p>Additional searches were performed in many of the sources listed above to cover the period after the last searches were performed for ALOIS, to ensure that the search for the review was as up‐to‐date and as comprehensive as possible. The search strategies used can be seen in <a href="./appendices#CD004744-sec-0078">Appendix 1</a> (the pre‐publication search), and in <a href="./appendices#CD004744-sec-0079">Appendix 2</a>. </p> <p>The latest search (February 2013) retrieved a total of 652 results. The latest search identified no new studies for inclusion in the review. </p> </section> </section> <section id="CD004744-sec-0025"> <h3 class="title" id="CD004744-sec-0025">Data collection and analysis</h3> <p>The two review authors independently discarded publications deemed to be irrelevant on the basis of title and abstract. Disagreements between the authors about final inclusion of trials were resolved by discussion, or by involving outside expert advice. </p> <section id="CD004744-sec-0026"> <h4 class="title">Quality assessment</h4> <p>The methodological quality of eligible trials was assessed, as low, unclear or high risk of bias using the Cochrane Collaboration handbook (<a href="./references#CD004744-bbs2-0017" title="HigginsJPT , GreenS (Editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD004744-sec-0027"> <h4 class="title">Data extraction</h4> <p>Data were extracted from the published reports. For each outcome assessed on a continuous scale the following statistics were required for each treatment group within each trial: mean change from baseline at endpoint, standard deviation of the mean change, and number of participants. Where changes from baseline were not reported, the mean, standard deviation and number of participants for each treatment group at each time point were extracted. </p> <p>For binary data the numbers in each treatment group and the numbers experiencing the outcome of interest were sought. </p> <p>The baseline assessment was defined as the latest available assessment prior to randomization, but not longer than two months prior. </p> <p>Data were sought for each outcome measure on every participant randomized. To allow an intention‐to‐treat analysis all randomized patients were included irrespective of compliance, whether or not the patient was subsequently deemed ineligible or otherwise excluded from treatment or follow up. If intention‐to‐treat data were not available in the publications, the data of those on treatment, or who complete the trial, were sought and indicated as such. </p> </section> <section id="CD004744-sec-0028"> <h4 class="title">Data analysis</h4> <p>The outcomes measured in clinical trials of dementia and cognitive impairment often arise from ordinal rating scales. Where the rating scales used in trials had a reasonably large number of ordered categories (more than 10), the data were treated as continuous outcomes arising from a normal distribution. </p> <p>Summary statistics (number of participants, mean and standard deviation) for change from baseline are required for each rating scale at each assessment time for each treatment group in each trial. </p> <p>When change from baseline results are not reported, the required summary statistics are calculated from the baseline and assessment time treatment group means and standard deviations. In this case a zero correlation between the measurements at baseline and assessment time is assumed. This method overestimates the standard deviation of the change from baseline, but this conservative approach is considered to be preferable in a meta‐analysis. </p> <p>Meta‐analysis requires the combination of data from trials that may not use the same rating scale to assess an outcome. The measure of treatment difference used for any outcome in the review will be the weighted mean difference when pooled trials used the same rating scale or test, and the standardised mean difference (i.e. the absolute mean difference divided by the standard deviation) when they used different rating scales or tests. </p> <p>The duration of trials may vary considerably. In future, if the range is considered too great to combine all trials into one meta‐analysis, it will be divided into smaller time periods, and a separate meta‐analysis conducted for each period. Some trials may contribute data to more than one time period, if multiple assessments have been done. </p> <p>For binary outcomes, such as clinical improvement or no clinical improvement, the odds ratio has been used to measure treatment effect. A weighted estimate of the typical treatment effect across trials will be calculated. </p> <p>In future, it is planned that overall estimates of the treatment difference will be presented. In all cases the overall estimate from a fixed‐effect model will be presented and a test for heterogeneity using a standard Chi<sup>2</sup> or the I<sup>2</sup> statistic will be performed. If, however, there is evidence of heterogeneity of the treatment effect between trials then only homogeneous results will be pooled or a random‐effects model will be used (in which case the confidence intervals would be broader than those of a fixed‐effect model). </p> </section> <section id="CD004744-sec-0029"> <h4 class="title">Subgroup analysis</h4> <p>Where relevant, and if data are available, future subgroup analyses will include age, sex, type and severity of impairment, and duration of treatment. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD004744-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD004744-sec-0030"></div> <section id="CD004744-sec-0031"> <h3 class="title">Description of studies</h3> <section id="CD004744-sec-0032"> <h4 class="title">Results of the search</h4> <p>The latest search performed in February 2013 did not identify any new studies for inclusion. </p> </section> <section id="CD004744-sec-0033"> <h4 class="title">Included studies</h4> <p>Three randomized placebo‐controlled trials were identified with 800 participants ‐ <a href="./references#CD004744-bbs2-0002" title="MokV , WongA , HoS , LeungT , LamWWM , WongKS . Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment2007;3(6):943‐8. ">Mok 2007</a>, <a href="./references#CD004744-bbs2-0001" title="BallardC , SauterM , ScheltensP , HeY , BarkhofF , vanStraatenEC , et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion2008;24(9):2561‐74. [PUBMED: 18674411] ">Ballard 2008</a> and <a href="./references#CD004744-bbs2-0003" title="NarasimhaluK , EffendyS , SimCH , LeeJM , ChenI , HiaSB , et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica2010;121:217‐24. ">Narasimhalu 2010</a>. For full details see <a href="./references#CD004744-sec-0088" title="">Characteristics of included studies</a>. </p> <p>The 26‐week study of <a href="./references#CD004744-bbs2-0002" title="MokV , WongA , HoS , LeungT , LamWWM , WongKS . Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment2007;3(6):943‐8. ">Mok 2007</a> included participants aged 40 to 90 years (mean ages 75.7 years in the rivastigmine arm and 74.1 years in the placebo arm) with subcortical vascular dementia, diagnosed according to standard criteria (<a href="./references#CD004744-bbs2-0012" title="ErkinjunttiT , InzitariD , PantoniL , WallinA , ScheltensP , RockwoodK , et al. Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission2000;59(Suppl):23‐30. ">Erkinjuntti 2000</a>). Forty participants were randomized. Average MMSE (mini‐mental state examination) scores were 13 and 13.4 in the active arm and placebo arm, respectively. </p> <p><a href="./references#CD004744-bbs2-0001" title="BallardC , SauterM , ScheltensP , HeY , BarkhofF , vanStraatenEC , et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion2008;24(9):2561‐74. [PUBMED: 18674411] ">Ballard 2008</a>, a 24‐week trial, included 710 participants with large and small vessel vascular dementia diagnosed according to NINDS‐AIREN and DSM‐IV criteria (<a href="./references#CD004744-bbs2-0032" title="RomanG , TatemichiT , ErkinjunttiT , CummingsJL , MasdeuJC , GarciaJH , et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology1993;43(2):250‐60. ">Roman 1993</a>; <a href="./references#CD004744-bbs2-0037" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders: Clinical Description and Diagnostic Guidelines. 10th Edition. Geneva: World Health organiazation, 1992. ">WHO 1992</a>). The majority met criteria for subcortical dementia as defined by <a href="./references#CD004744-bbs2-0012" title="ErkinjunttiT , InzitariD , PantoniL , WallinA , ScheltensP , RockwoodK , et al. Research criteria for subcortical vascular dementia in clinical trials. Journal of Neural Transmission2000;59(Suppl):23‐30. ">Erkinjuntti 2000</a> according to MRI criteria (69.9% in the rivastigmine arm and 72.5% in the placebo arm). Age ranged from 50 to 85 years (mean ages 72.9 years in the rivastigmine group and 72.7 years in the placebo group). The average MMSE in both arms was 19.2. </p> <p>The <a href="./references#CD004744-bbs2-0003" title="NarasimhaluK , EffendyS , SimCH , LeeJM , ChenI , HiaSB , et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica2010;121:217‐24. ">Narasimhalu 2010</a> trial included 50 participants with ischaemic stroke who failed to meet standard criteria for dementia, but exhibited some cognitive impairment. Their ages ranged from 48 to 84 years (mean ages 68.1 years in the rivastigmine group and 69.4 years in the placebo group). Trial duration was 24 weeks. The MMSE in the rivastigmine arm was 23.7 and 23.9 in the placebo arm. </p> <p>Particpants were recruited from a variety of settings. <a href="./references#CD004744-bbs2-0002" title="MokV , WongA , HoS , LeungT , LamWWM , WongKS . Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment2007;3(6):943‐8. ">Mok 2007</a> included people from a Chinese background, <a href="./references#CD004744-bbs2-0001" title="BallardC , SauterM , ScheltensP , HeY , BarkhofF , vanStraatenEC , et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion2008;24(9):2561‐74. [PUBMED: 18674411] ">Ballard 2008</a> included people from different centres across the world including Europe, Asia, Russia and USA. <a href="./references#CD004744-bbs2-0003" title="NarasimhaluK , EffendyS , SimCH , LeeJM , ChenI , HiaSB , et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica2010;121:217‐24. ">Narasimhalu 2010</a> included participants from Singapore. </p> <p>Study screening in all cases excluded people with a diagnosis of dementia other than that due to a vascular cause, and cases of depression and physical illness of an unstable nature that might potentially limit involvement in all phases of the study. </p> <section id="CD004744-sec-0034"> <h5 class="title">Outcome measures and rating scales</h5> <section id="CD004744-sec-0035"> <h6 class="title">1. Alzheimer's Disease Assessment Scale ‐ Cognitive (ADAS‐Cog)</h6> <p>The Alzheimer's Disease Assessment Scale is comprised of 11 individual tests (<a href="./references#CD004744-bbs2-0033" title="RosenWG , MohsRC , DavisKL . A new rating scale for Alzheimer's disease. The American Journal of Psychiatry1984;141(11):1356‐64. [PUBMED: 6496779] ">Rosen 1984</a>): spoken language ability (unless indicated otherwise these tests are scored from 0 to 5), comprehension of spoken language, recall of test instructions, word finding difficulty, following commands, naming objects, construction drawing, ideational praxis, orientation (0 to 8), word recall (0 to 10) and word recognition (0 to 12). The total score ranges from 0 to 70, with higher scores indicating greater impairment. </p> </section> <section id="CD004744-sec-0036"> <h6 class="title">2. Global Deterioration Scale (GDS)</h6> <p>The Global Deterioration Scale is a global assessment of severity of dementia carried out by a clinician with access to all information about a patient (<a href="./references#CD004744-bbs2-0031" title="ReisbergB , FerrisSH , deLeonMJ , CrookT . The Global Deterioration Scale for assessment of primary degenerative dementia. The American Journal of Psychiatry1982;139(9):1136‐9. [PUBMED: 7114305] ">Reisberg 1982</a>). Scores range from 1 to 7, with 1 indicating normal and 7 indicating severe dementia. </p> </section> <section id="CD004744-sec-0037"> <h6 class="title">3. Mini Mental State Examination (MMSE)</h6> <p>The Mini Mental State Examination evaluates cognition in five domains (<a href="./references#CD004744-bbs2-0014" title="FolsteinMF , FolsteinSE , McHughPR . 'Mini‐Mental State': A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research1975;12:189‐98. ">Folstein 1975</a>); orientation, immediate recall, attention and calculation, delayed recall and language. The test takes 15 minutes to administer. Scores range from 0 (severe impairment) to 30 (normal). </p> </section> <section id="CD004744-sec-0038"> <h6 class="title">4. Alzheimer's Disease Cooperative Study activities of daily living scale (ADCS‐ADL)</h6> <p>The Alzheimer's Disease Cooperative Study activities of daily living is a 19‐item scale assessing basic and complex abilities in people with dementia (<a href="./references#CD004744-bbs2-0015" title="GalaskoD , BennettD , SanoM , ErnestoC , ThomasR , GrundmanM , et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11 Suppl 2:S33‐9. [PUBMED: 9236950] ">Galasko 1997</a>). Items include activities such as eating, bathing, operating taps, and switching of lights. Scores range from 0 (severe impairment) to 54 (no impairment). </p> </section> <section id="CD004744-sec-0039"> <h6 class="title">5. Neuropsychiatric Instrument (NPI)</h6> <p>The Neuropsychiatric Instrument is a 12‐item carer‐rated instrument that evaluates behavioural and neuropsychiatric symptoms, including delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy, disinhibition, irritability, aberrant motor behaviour, night‐time behaviour and eating/appetite disorder (<a href="./references#CD004744-bbs2-0009" title="CummingsJL . Frontal‐subcortical circuits and human behavior. Archives of Neurology1993;50(8):873‐80. ">Cummings 1993</a>). Frequency is rated from 1 (occasional, less than once a week) to 4 (very frequent). Severity is rated from 1 (mild) to 3 (severe). The product of frequency and severity ranges from 1 to 12 for each item, and total scores range from 12 to 120. </p> </section> <section id="CD004744-sec-0040"> <h6 class="title">6. Clinical Dementia rating scale ‐ sum of boxes (CDR‐SB)</h6> <p>Clinical Dementia rating scale ‐ sum of boxes ‐ is derived from ratings in six domains (memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care) (<a href="./references#CD004744-bbs2-0025" title="MorrisJC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993;43(11):2412‐4. [PUBMED: 8232972] ">Morris 1993</a>); each domain is scored from 0 (normal) to 3 (severe dementia). The sum (0 to 18) is the CDR‐SB. </p> </section> <section id="CD004744-sec-0041"> <h6 class="title">7. Vascular Dementia Assessment Scale (VaDAS)</h6> <p>The Vascular Dementia Assessment Scale comprises the 13‐item ADAS‐Cog plus five additional tests to assess cognitive features that may be more predominant in vascular dementia, such as executive dysfunction (symbol digit modalities test, digit backwards, maze, digit cancellation task, verbal fluency) (<a href="./references#CD004744-bbs2-0013" title="FerrisSH . Cognitive outcome measures. Alzheimer Disease and Associated Disorders1999;13 Suppl 3:S140‐2. [PUBMED: 10609693] ">Ferris 1999</a>). Total scores range from 0 to 110. </p> </section> <section id="CD004744-sec-0042"> <h6 class="title">8. Alzheimer's Disease Cooperative Study Clinical Global Impression of Change scale (ADCS‐CGIC) </h6> <p>The Alzheimer's Disease Cooperative Study Clinical Global Impression of Change scale reports a single global rating of change from baseline using a seven‐point scale, where 1 represents marked improvement and 7 represents marked worsening (<a href="./references#CD004744-bbs2-0034" title="SchneiderLS , OlinJT , DoodyRS , ClarkCM , MorrisJC , ReisbergB , et al. Validity and reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11 Suppl 2:S22‐32. [PUBMED: 9236949] ">Schneider 1997</a>). </p> </section> <section id="CD004744-sec-0043"> <h6 class="title">9. Chinese version of MMSE</h6> <p>The Chinese version of the MMSE assesses cognition in five domains in a similar way to the original MMSE. Further details about this version of the MMSE are described in <a href="./references#CD004744-bbs2-0007" title="ChiuHFK , LeeHC , ChungWS , KwongPK . The reliability and validity of the Cantonese version of Mini‐Mental State Examination. East Asian Archives of Psychiatry: Official Journal of the Hong Kong College of Psychiatrists1994;4 (Supp 2):25‐8. ">Chiu 1994</a>. </p> </section> <section id="CD004744-sec-0044"> <h6 class="title">10. Frontal Assessment Battery (FAB)</h6> <p>The frontal assessment battery evaluates executive function and consists of six items, each evaluating one executive domain (conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control and environment autonomy) (<a href="./references#CD004744-bbs2-0011" title="DuboisB , SlachevskyA , LitvanI , PillonB . The FAB: a Frontal Assessment Battery at bedside. Neurology2000;55(11):1621‐6. [PUBMED: 11113214] ">Dubois 2000</a>; <a href="./references#CD004744-bbs2-0023" title="MokVC , WongA , YimP , FuM , LamWW , HuiAC , et al. The validity and reliability of chinese frontal assessment battery in evaluating executive dysfunction among Chinese patients with small subcortical infarct. Alzheimer Disease and Associated Disorders2004;18:68‐74. ">Mok 2004</a>). </p> </section> <section id="CD004744-sec-0045"> <h6 class="title">11. Chinese version of the Instrumental Activities of Daily Living scale (Chinese‐IADL)</h6> <p>The Chinese version of the Instrumental Activities of Daily Living scale assess performance of daily activities (use of telephone, transportation, shopping, meal preparation, housework, handyman work, laundry, medication management and money management) (<a href="./references#CD004744-bbs2-0036" title="TongAYC , ManDWK . The Validation of the Hong Kong Chinese Version of the Lawton Instrumental Activities of Daily Living Scale for institutionalized elderly persons.. Occupation, Participation and Health2002;22(4):132. ">Tong 2002</a>). The score for each item ranges from 0 to 3. Lower scores indicate better function. </p> </section> <section id="CD004744-sec-0046"> <h6 class="title">12. Ten‐Point Clock test</h6> <p>The Ten‐Point Clock test assesses the correct drawing of a clock showing the time 11.10 (<a href="./references#CD004744-bbs2-0022" title="ManosPJ , WuR . The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. International Journal of Psychiatry in Medicine1994;24(3):229‐44. [PUBMED: 7890481] ">Manos 1994</a>). Maximum score is 10 points, with 0 indicating severe dementia. </p> </section> <section id="CD004744-sec-0047"> <h6 class="title">13. Color Trails 1 and Color Trails 2</h6> <p>The Color Trail 1 test assesses the ability of the patient to connect circles numbered 1 to 25 in the correct sequence with a pencil line (<a href="./references#CD004744-bbs2-0010" title="D'eliaLSP , UchiyamaCL , WhiteT . Colour Trails Test. Psychological Assessment Resources Inc. PAR, 1996. ">D'elia 1996</a>). The second test is a variation where the patient is asked to alternate between pink and yellow circles. Higher scores indicate more severe dementia. </p> </section> <section id="CD004744-sec-0048"> <h6 class="title">14. Geriatric Depression Scale (GDS)</h6> <p>The Geriatric Depression Scale scores 30 items to assess degree of depression 0 to 30 (severe depression) (<a href="./references#CD004744-bbs2-0038" title="YesavageJA , BrinkTL , RoseTL , LumO , HuangV , AdeyM , et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research1982;17(1):37‐49. [PUBMED: 7183759] ">Yesavage 1982</a>). </p> <p>The included trials used a variety of scales/instruments to assess their participants. <a href="./references#CD004744-bbs2-0002" title="MokV , WongA , HoS , LeungT , LamWWM , WongKS . Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment2007;3(6):943‐8. ">Mok 2007</a> assessed participants with the MMSE (<a href="./references#CD004744-bbs2-0007" title="ChiuHFK , LeeHC , ChungWS , KwongPK . The reliability and validity of the Cantonese version of Mini‐Mental State Examination. East Asian Archives of Psychiatry: Official Journal of the Hong Kong College of Psychiatrists1994;4 (Supp 2):25‐8. ">Chiu 1994</a>), FAB (<a href="./references#CD004744-bbs2-0011" title="DuboisB , SlachevskyA , LitvanI , PillonB . The FAB: a Frontal Assessment Battery at bedside. Neurology2000;55(11):1621‐6. [PUBMED: 11113214] ">Dubois 2000</a>), NPI (<a href="./references#CD004744-bbs2-0020" title="LeungVP , LamLC , ChiuHF , CummingsJL , ChenQL . Validation study of the Chinese version of the neuropsychiatric inventory (CNPI). International Journal of Geriatric Psychiatry2001;16(8):789‐93. [PUBMED: 11536346] ">Leung 2001</a>), instrumental activities of daily living (IADL) (<a href="./references#CD004744-bbs2-0036" title="TongAYC , ManDWK . The Validation of the Hong Kong Chinese Version of the Lawton Instrumental Activities of Daily Living Scale for institutionalized elderly persons.. Occupation, Participation and Health2002;22(4):132. ">Tong 2002</a>), and CDR‐SB (<a href="./references#CD004744-bbs2-0025" title="MorrisJC . The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology1993;43(11):2412‐4. [PUBMED: 8232972] ">Morris 1993</a>). </p> <p>The <a href="./references#CD004744-bbs2-0001" title="BallardC , SauterM , ScheltensP , HeY , BarkhofF , vanStraatenEC , et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion2008;24(9):2561‐74. [PUBMED: 18674411] ">Ballard 2008</a> trial based its primary efficacy measures on VaDAS (<a href="./references#CD004744-bbs2-0013" title="FerrisSH . Cognitive outcome measures. Alzheimer Disease and Associated Disorders1999;13 Suppl 3:S140‐2. [PUBMED: 10609693] ">Ferris 1999</a>), and the ADCS‐CGIC (<a href="./references#CD004744-bbs2-0034" title="SchneiderLS , OlinJT , DoodyRS , ClarkCM , MorrisJC , ReisbergB , et al. Validity and reliability of the Alzheimer's Disease Cooperative Study‐Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11 Suppl 2:S22‐32. [PUBMED: 9236949] ">Schneider 1997</a>). Secondary endpoints included the MMSE and NPI as well as ADAS‐Cog (<a href="./references#CD004744-bbs2-0033" title="RosenWG , MohsRC , DavisKL . A new rating scale for Alzheimer's disease. The American Journal of Psychiatry1984;141(11):1356‐64. [PUBMED: 6496779] ">Rosen 1984</a>), and ADCS‐ADL (<a href="./references#CD004744-bbs2-0015" title="GalaskoD , BennettD , SanoM , ErnestoC , ThomasR , GrundmanM , et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders1997;11 Suppl 2:S33‐9. [PUBMED: 9236950] ">Galasko 1997</a>). This study also included the global deterioration scale (GDS) (<a href="./references#CD004744-bbs2-0031" title="ReisbergB , FerrisSH , deLeonMJ , CrookT . The Global Deterioration Scale for assessment of primary degenerative dementia. The American Journal of Psychiatry1982;139(9):1136‐9. [PUBMED: 7114305] ">Reisberg 1982</a>). </p> <p>Within <a href="./references#CD004744-bbs2-0003" title="NarasimhaluK , EffendyS , SimCH , LeeJM , ChenI , HiaSB , et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica2010;121:217‐24. ">Narasimhalu 2010</a>, the outcomes included MMSE, ADAS‐Cog, FAB, ADCS‐ADL, NPI. In this study also used the geriatric depression scale (GDS, <a href="./references#CD004744-bbs2-0038" title="YesavageJA , BrinkTL , RoseTL , LumO , HuangV , AdeyM , et al. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research1982;17(1):37‐49. [PUBMED: 7183759] ">Yesavage 1982</a>),along with the Ten‐Point Clock test and Color Trails tests 1 and 2. </p> <p>Treatment in <a href="./references#CD004744-bbs2-0002" title="MokV , WongA , HoS , LeungT , LamWWM , WongKS . Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment2007;3(6):943‐8. ">Mok 2007</a> was started at 1.5 mg rivastigmine twice a day, and increased to 3 mg twice a day after four weeks. In <a href="./references#CD004744-bbs2-0001" title="BallardC , SauterM , ScheltensP , HeY , BarkhofF , vanStraatenEC , et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion2008;24(9):2561‐74. [PUBMED: 18674411] ">Ballard 2008</a> treatment began at 1.5 mg rivastigmine twice a day, and increased by 1.5 mg twice a day increments at four‐weekly intervals, until the highest well tolerated dose was reached (average daily dose 9.4 mg). The titration regimen of <a href="./references#CD004744-bbs2-0003" title="NarasimhaluK , EffendyS , SimCH , LeeJM , ChenI , HiaSB , et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica2010;121:217‐24. ">Narasimhalu 2010</a> was similar, although a ceiling of 4.5 mg twice a day was employed. </p> <p>All three studies tabulated the extent of adverse side effects.</p> </section> </section> <section id="CD004744-sec-0049"> <h5 class="title">Quality assessment</h5> <p>The <a href="./references#CD004744-bbs2-0002" title="MokV , WongA , HoS , LeungT , LamWWM , WongKS . Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment2007;3(6):943‐8. ">Mok 2007</a> efficacy analysis was performed on an intention‐to‐treat (ITT) basis. One participant died within the placebo arm after the first assessment. The analysis in <a href="./references#CD004744-bbs2-0001" title="BallardC , SauterM , ScheltensP , HeY , BarkhofF , vanStraatenEC , et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion2008;24(9):2561‐74. [PUBMED: 18674411] ">Ballard 2008</a> had an ITT basis for all randomized participants, an observed case analysis for participants available at evaluation, and a last observation carried forward approach (i.e. the DNDP‐LOCF, division of neuropharmacological drug products last observation carried forward), where one dose and one evaluation was the minimum engagement. Within this study, 75.3% completed the treatment on rivastigmine and 86.1% completed the placebo arm. <a href="./references#CD004744-bbs2-0003" title="NarasimhaluK , EffendyS , SimCH , LeeJM , ChenI , HiaSB , et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica2010;121:217‐24. ">Narasimhalu 2010</a> analysed via ITT and noted one death during the study within the placebo arm. </p> </section> </section> <section id="CD004744-sec-0050"> <h4 class="title">Excluded studies</h4> <p>There were no excluded studies.</p> </section> </section> <section id="CD004744-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>Three randomized, placebo controlled studies were included. For full details see 'risk of bias' tables in the <a href="./references#CD004744-sec-0088" title="">Characteristics of included studies</a> below. </p> </section> <section id="CD004744-sec-0052"> <h3 class="title" id="CD004744-sec-0052">Effects of interventions</h3> <p>Data from the three included studies could not be combined because the study populations differed in degree of cognitive impairment (from severe dementia to non‐demented), and the target treatment dose of rivastigmine was different. </p> <section id="CD004744-sec-0053"> <h4 class="title">Ballard 2008</h4> <section id="CD004744-sec-0054"> <h5 class="title">Cognition</h5> <p>This study showed benefit at 24 weeks associated with rivastigmine (3 mg to 12mg/day) compared with placebo for the VaDAS, ADAS‐Cog and MMSE assessments: </p> <p>VaDAS (MD ‐1.30, 95% CI ‐2.62 to 0.02, P value 0.05) (<a href="./references#CD004744-fig-0001" title="">Analysis 1.1</a>); </p> <p>MMSE (MD 0.60, 95% CI 0.11 to 1.09, P value 0.02) (<a href="./references#CD004744-fig-0002" title="">Analysis 1.2</a>); </p> <p>ADAS‐Cog (MD ‐1.10, 95% CI ‐2.15 to ‐0.05, P value 0.04) (<a href="./references#CD004744-fig-0003" title="">Analysis 1.3</a>). </p> </section> <section id="CD004744-sec-0055"> <h5 class="title">Global</h5> <p>There was no statistically significant difference between rivastigmine (3 mg to 12 mg/day) and placebo groups for the ADCS‐CGIC and GDS assessments (MD ‐0.10, 95% CI ‐3.68 to 3.48, P value 0.96 (<a href="./references#CD004744-fig-0004" title="">Analysis 1.4</a>); and MD ‐0.1, 95% CI ‐0.21 to 0.01, P value 0.08 (<a href="./references#CD004744-fig-0005" title="">Analysis 1.5</a>), respectively). </p> </section> <section id="CD004744-sec-0056"> <h5 class="title">Behavioural disturbance</h5> <p>There was no statistically significant difference between rivastigmine (3 mg to 12 mg/day) and placebo groups for the NPI‐12 assessments (MD 0.40, 95% CI ‐1.36 to 2.16, P value 0.66) (<a href="./references#CD004744-fig-0006" title="">Analysis 1.6</a>). </p> </section> <section id="CD004744-sec-0057"> <h5 class="title">Activities of daily living</h5> <p>There was no statistically significant difference between rivastigmine (3 mg to 12 mg/day) and placebo groups for the ADCS‐ADL assessments (MD 0.60, 95% CI ‐1.05 to 2.25, P value 0.48) (<a href="./references#CD004744-fig-0007" title="">Analysis 1.7</a>) </p> </section> <section id="CD004744-sec-0058"> <h5 class="title">Adverse effects</h5> <p>This study showed a significant difference in withdrawals before the end of treatment, with more participants withdrawing from the rivastigmine group than from the placebo group (rivastigmine 90/365, placebo 48/345, OR 2.02, 95% CI 1.38 to 2.98, P value 0.0003) (<a href="./references#CD004744-fig-0008" title="">Analysis 1.8</a>). Again, there were more withdrawals before end of treatment due to an adverse event in the rivastigmine group than in the placebo group (rivastigmine 49/365, placebo 19/345, OR 2.66, 95% CI 1.53 to 4.62, P value 0.0005) (<a href="./references#CD004744-fig-0009" title="">Analysis 1.9</a>). </p> <p>A greater number of some adverse effects (nausea, vomiting, diarrhoea and anorexia) were documented in the rivastigmine group than in the placebo group: </p> <p>at least one adverse event of nausea (rivastigmine 96/365, placebo 13/345, OR 9.15, 95% CI 5.02 to 16.70, P value &lt; 0.00001) (<a href="./references#CD004744-fig-0011" title="">Analysis 1.11</a>); </p> <p>at least one adverse event of vomiting (rivastigmine 80/365, placebo 8/345, OR 11.87, 95% CI 5.64 to 24.98, P value &lt; 0.00001) (<a href="./references#CD004744-fig-0012" title="">Analysis 1.12</a>); </p> <p>at least one adverse event of diarrhoea (rivastigmine 33/365, placebo 15/345, OR 2.19, 95% CI 1.17 to 4.11, P value 0.01) (<a href="./references#CD004744-fig-0013" title="">Analysis 1.13</a>); </p> <p>at least one adverse event of anorexia (rivastigmine 19/365, placebo 6/345, OR 3.11, 95% CI 1.23 to 7.89, P value 0.02) (<a href="./references#CD004744-fig-0019" title="">Analysis 1.19</a>); </p> <p>However, there was no difference between the rivastigmine and placebo groups for other adverse effects (numbers of deaths, dizziness, falls, hypertension, hypotension, headache, bradycardia, serious adverse events, and at least one serious adverse event due to a cerebrovascular accident): </p> <p>numbers of deaths (rivastigmine 8/365, placebo 4/345, OR 1.91, 95% CI 0.57 to 6.40, P value 0.29) (<a href="./references#CD004744-fig-0010" title="">Analysis 1.10</a>); </p> <p>at least one adverse event of dizziness (rivastigmine 29/363, placebo 17/344, OR 1.67, 95% CI 0.90 to 3.10, P value 0.10) (<a href="./references#CD004744-fig-0014" title="">Analysis 1.14</a>); </p> <p>at least one adverse event of a fall (rivastigmine 24/363, placebo 17/344, OR 1.36, 95% CI 0.72 to 2.58, P value 0.34) (<a href="./references#CD004744-fig-0015" title="">Analysis 1.15</a>); </p> <p>at least one adverse event of hypertension (rivastigmine 20/363, placebo 10/344, OR 0.95, 95% CI 0.90 to 4.22, P value 0.09) (<a href="./references#CD004744-fig-0016" title="">Analysis 1.16</a>); </p> <p>at least one adverse event of hypotension (rivastigmine 5/363, placebo 4/344, OR 1.19, 95% CI 0.32 to 4.46, P value 0.80) (<a href="./references#CD004744-fig-0017" title="">Analysis 1.17</a>); </p> <p>at least one adverse event of headache (rivastigmine 19/363, placebo 10/344, OR 1.84, 95% CI (0.85 to 4.03, P value 0.12) (<a href="./references#CD004744-fig-0018" title="">Analysis 1.18</a>; </p> <p>at least one adverse event of bradycardia (rivastigmine 5/363, placebo 5/344, OR 0.95, 95% CI 0.27 to 3.30, P value 0.93) (<a href="./references#CD004744-fig-0020" title="">Analysis 1.20</a>); </p> <p>at least one serious adverse event (rivastigmine 55/363, placebo 38/344, OR 1.44, 95% CI 0.92 to 2.24, P value 0.11) (<a href="./references#CD004744-fig-0021" title="">Analysis 1.21</a>); </p> <p>at least one serious adverse event due to, or potentially due to, a cerebrovascular accident (rivastigmine 20/363, placebo 15/344, OR 1.28, 95% CI 0.64 to 2.54, P value 0.48) (<a href="./references#CD004744-fig-0022" title="">Analysis 1.22</a>). </p> </section> </section> <section id="CD004744-sec-0059"> <h4 class="title">Mok 2007</h4> <section id="CD004744-sec-0060"> <h5 class="title">Cognition</h5> <p>There was no statistically significant difference between the rivastigmine and placebo groups for the MMSE (MD 0.70, 95% CI ‐1.78 to 3.18, P value 0.58) (<a href="./references#CD004744-fig-0023" title="">Analysis 2.1</a>), FAB (MD ‐0.40, 95% CI ‐1.52 to 0.72, P value 0.48) (<a href="./references#CD004744-fig-0024" title="">Analysis 2.2</a>), or any of the FAB sub‐items (conceptualisation, mental flexibility, programming, sensitivity to interference, inhibitory control, environmental autonomy). </p> </section> <section id="CD004744-sec-0061"> <h5 class="title">Global</h5> <p>There was no statistically significant difference between rivastigmine and placebo groups for CDR‐sum of boxes (MD 0.30, 95% CI ‐3.11 to 3.71, P value 0.86) (<a href="./references#CD004744-fig-0025" title="">Analysis 2.3</a>). </p> </section> <section id="CD004744-sec-0062"> <h5 class="title">Behavioural disturbance</h5> <p>There was no statistically significant difference between rivastigmine and placebo groups for the NPI (MD ‐4.50, 95% CI ‐13.18 to 4.18, P value 0.31) (<a href="./references#CD004744-fig-0026" title="">Analysis 2.4</a>). </p> </section> <section id="CD004744-sec-0063"> <h5 class="title">Activities of daily living</h5> <p>There was no statistically significant difference between rivastigmine and placebo groups for IADL (MD 0.10, 95% CI ‐0.12 to 0.32, P value 0.37) (<a href="./references#CD004744-fig-0027" title="">Analysis 2.5</a>). </p> </section> <section id="CD004744-sec-0064"> <h5 class="title">Adverse effects</h5> <p>There was one death within the placebo arm (haemorrhagic stroke), but none within the rivastigmine arm. There were no significant treatment effects relating to number of withdrawals before end of treatment (rivastigmine 6/20, placebo 3/20, OR 2.43, 95% CI 0.51 to 11.51, P value 0.26) (<a href="./references#CD004744-fig-0028" title="">Analysis 2.6</a>), or numbers of participants suffering an adverse event (rivastigmine 12/20, placebo 10/20, OR 1.50, 95% CI 0.43 to 5.25, P value 0.53) (<a href="./references#CD004744-fig-0029" title="">Analysis 2.7</a>). </p> </section> </section> <section id="CD004744-sec-0065"> <h4 class="title">Narasimhalu 2010</h4> <section id="CD004744-sec-0066"> <h5 class="title">Cognition</h5> <p>There was no statistically significant difference between rivastigmine (3 mg to 9 mg/d) and placebo groups for clock drawing (MD ‐0.40, 95% CI ‐1.58 to 0.78, P value 0.51) (<a href="./references#CD004744-fig-0032" title="">Analysis 3.1</a>), color trails 1 (MD 8.70, 95% CI ‐20.16 to 37.56, P value 0.55) (<a href="./references#CD004744-fig-0033" title="">Analysis 3.2</a>) and 2 (MD ‐15.50, 95% CI ‐34.75 to 3.75, P value 0.11) (<a href="./references#CD004744-fig-0034" title="">Analysis 3.3</a>), and ADAS‐Cog (MD 2.20, 95% CI ‐1.40 to 5.80, P value 0.23) (<a href="./references#CD004744-fig-0035" title="">Analysis 3.4</a>) assessments. </p> </section> <section id="CD004744-sec-0067"> <h5 class="title">Behavioural disturbance</h5> <p>There was no statistically significant difference between rivastigmine (3 mg to 9 mg/d) and placebo groups for the NPI assessments (MD 0.21, 95% CI ‐2.61 to 3.03, P value 0.88) (<a href="./references#CD004744-fig-0036" title="">Analysis 3.5</a>). </p> </section> <section id="CD004744-sec-0068"> <h5 class="title">Activities of daily living</h5> <p>There was no statistically significant difference between rivastigmine (3 mg to 9 mg/d) and placebo groups for the ADCS‐ADL assessments (MD ‐2.00, 95% CI ‐6.96 to 2.96, P value 0.43) (<a href="./references#CD004744-fig-0038" title="">Analysis 3.7</a>). </p> </section> <section id="CD004744-sec-0069"> <h5 class="title">Mood</h5> <p>There was no statistically significant difference between rivastigmine (3 mg to 9 mg/d) and placebo groups for the GDS assessments (MD 0.90, 95% CI ‐0.94 to 2.74, P value 0.34) (<a href="./references#CD004744-fig-0037" title="">Analysis 3.6</a>). </p> </section> <section id="CD004744-sec-0070"> <h5 class="title">Adverse events</h5> <p>There was no statistically significant difference between rivastigmine compared with placebo for: </p> <p>numbers of deaths (rivastigmine 1/25, placebo 1/25, OR 1.00, 95% CI 0.06 to 16.93, P value 1.00) (<a href="./references#CD004744-fig-0042" title="">Analysis 3.11</a>); </p> <p>numbers of participants suffering at least one adverse event (rivastigmine 9/25, placebo 10/25, OR 0.84, 95% CI 0.27 to 2.65, P value 0.77) (<a href="./references#CD004744-fig-0040" title="">Analysis 3.9</a>); </p> <p>numbers of participants suffering at least one adverse event of nausea (rivastigmine 1/25, placebo 0/25, OR 3.12, 95% CI 0.12 to 80.39, P value 0.49) (<a href="./references#CD004744-fig-0043" title="">Analysis 3.12</a>); </p> <p>numbers of participants suffering at least one adverse event of diarrhoea (rivastigmine 1/25, placebo 0/25, OR 3.12, 95% CI 0.12 to 80.39, P value 0.49) (<a href="./references#CD004744-fig-0047" title="">Analysis 3.16</a>), </p> <p>numbers of participants suffering at least one adverse event of dizziness (rivastigmine 2/25, placebo 0/25, OR 5.43, 95% CI 0.25 to 118.96, P value 0.28) (<a href="./references#CD004744-fig-0048" title="">Analysis 3.17</a>); </p> <p>numbers of participants suffering at least one adverse event of vomiting (rivastigmine 3/25, placebo 0/25, OR 7.93, 95% CI 0.39 to 162.07, P value 0.18) (<a href="./references#CD004744-fig-0049" title="">Analysis 3.18</a>); </p> <p>numbers of participants suffering at least one adverse event of gastrointestinal upset (rivastigmine 1/25, placebo 1/25, OR 1.00, 95% CI 0.06 to 16.93, P value 1.00) (<a href="./references#CD004744-fig-0045" title="">Analysis 3.14</a>); </p> <p>numbers of participants suffering at least one adverse event of headache (rivastigmine 1/25, placebo 2/25, OR 0.78, 95% CI 0.04 to 5.65, P value 0.56) (<a href="./references#CD004744-fig-0044" title="">Analysis 3.13</a>); </p> <p>numbers of participants suffering at least one adverse event of breathlessness (rivastigmine 1/25, placebo 1/25, OR 1.00, 95% CI 0.06 to 16.93, P value 1.00) (<a href="./references#CD004744-fig-0046" title="">Analysis 3.15</a>); </p> <p>numbers of participants suffering at least one adverse event of chest pain (rivastigmine 2/25, placebo 0/25, OR 5.43, 95% CI 0.25 to 118.96, P value 0.28) (<a href="./references#CD004744-fig-0050" title="">Analysis 3.19</a>); </p> <p>numbers of participants suffering at least one adverse event of accidental fall (rivastigmine 0/25, placebo 1/25, OR 0.32, 95% CI 0.01 to 8.25, P value 0.49) (<a href="./references#CD004744-fig-0051" title="">Analysis 3.20</a>), and </p> <p>numbers of participants suffering at least one serious adverse event (rivastigmine 5/25, placebo 5/25, OR 1.00, 95% CI 0.25 to 4.00, P value 1.00) (<a href="./references#CD004744-fig-0041" title="">Analysis 3.10</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD004744-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD004744-sec-0071"></div> <p>Two of the three included studies had small numbers of participants: <a href="./references#CD004744-bbs2-0002" title="MokV , WongA , HoS , LeungT , LamWWM , WongKS . Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment2007;3(6):943‐8. ">Mok 2007</a> had 40 participants, and <a href="./references#CD004744-bbs2-0003" title="NarasimhaluK , EffendyS , SimCH , LeeJM , ChenI , HiaSB , et al. A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica2010;121:217‐24. ">Narasimhalu 2010</a> had 50, divided equally into active (rivastigmine) and placebo arms. These studies were inadequately powered. Thus, conclusions are necessarily limited and an inability to detect an effect size is a potential weakness. </p> <p>The <a href="./references#CD004744-bbs2-0001" title="BallardC , SauterM , ScheltensP , HeY , BarkhofF , vanStraatenEC , et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Current medical research and opinion2008;24(9):2561‐74. [PUBMED: 18674411] ">Ballard 2008</a> trial, however, included 710 participants at study commencement. It demonstrated superiority of rivastigmine over placebo for several cognitive measures. It should be noted that the 24‐week duration of the trial was short, given that vascular cognitive impairment (VCI) is a chronic illness with an uncertain natural history in terms of both survival and rate of decline (<a href="./references#CD004744-bbs2-0005" title="BruandetA , RichardF , BomboisS , MaurageCA , DeramecourtV , LebertF , et al. Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. Journal of Neurology, Neurosurgery, and Psychiatry2009;80(2):133‐9. [PUBMED: 18977819] ">Bruandet 2009</a>). </p> <p>Unfortunately, trials within the area of VCI or vascular dementia are problematic. Uncertainties around diagnosis make it difficult to identify a target population (<a href="./references#CD004744-bbs2-0018" title="KerolaT , KettunenR , NieminenT . The complex interplay of cardiovascular system and cognition: How to predict dementia in the elderly?. International Journal of Cardiology2010;150(2):123‐9. [PUBMED: 21094551] ">Kerola 2010</a>; <a href="./references#CD004744-bbs2-0026" title="Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late‐onset dementia in a multicentre, community‐based population in England and Wales. The Lancet2001;357:169‐75. ">MRC CFAS 2001</a>). It is recognised increasingly that vascular risk factors influence the development of AD (<a href="./references#CD004744-bbs2-0019" title="KivipeltoM , NganduT , FratiglioniL , ViitanenM , KareholtI , WinbladB , et al. Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Archives of Neurology2005;62(10):1556‐60. [PUBMED: 16216938] ">Kivipelto 2005</a>), and there is a limited knowledge base concerning the effect of coexisting dementias on outcome and response (<a href="./references#CD004744-bbs2-0004" title="BlackSE . Vascular cognitive impairment: epidemiology, subtypes, diagnosis and management. The journal of the Royal College of Physicians of Edinburgh2011;41(1):49‐56. [PUBMED: 21365068] ">Black 2011</a>). </p> <p>Further trials are required before rivastigmine can be recommended for the treatment of vascular dementia or VCI. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD004744-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 1 VaDAS (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 1 VaDAS (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 2 MMSE (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 2 MMSE (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 3 ADAS‐Cog (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 3 ADAS‐Cog (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 4 ADCS‐CGIC 24 weeks ITT." data-id="CD004744-fig-0004" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 4 ADCS‐CGIC 24 weeks ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 5 GDS global deterioration scale (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0005" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 5 GDS global deterioration scale (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 6 Behavioural disturbance NPI‐12 (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0006" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 6 Behavioural disturbance NPI‐12 (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 7 ADCS‐ADL (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0007" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 7 ADCS‐ADL (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 8 Withdrawals before end of treatment at 24 weeks." data-id="CD004744-fig-0008" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 8 Withdrawals before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 9 Withdrawals due to adverse event by 24 weeks." data-id="CD004744-fig-0009" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 9 Withdrawals due to adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 10 Deaths by 24 weeks." data-id="CD004744-fig-0010" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 10 Deaths by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 11 At least one adverse event of nausea by 24 weeks." data-id="CD004744-fig-0011" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 11 At least one adverse event of nausea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 12 At least one adverse event of vomiting by 24 weeks." data-id="CD004744-fig-0012" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 12 At least one adverse event of vomiting by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 13 At least one adverse event of diarrhoea by 24 weeks." data-id="CD004744-fig-0013" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 13 At least one adverse event of diarrhoea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 14 At least one adverse event of dizziness by 24 weeks." data-id="CD004744-fig-0014" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 14 At least one adverse event of dizziness by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 15 At least one adverse event of a fall by 24 weeks." data-id="CD004744-fig-0015" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 15 At least one adverse event of a fall by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 16 At least one adverse event of hypertension by 24 weeks." data-id="CD004744-fig-0016" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 16 At least one adverse event of hypertension by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 17 At least one adverse event of hypotension by 24 weeks." data-id="CD004744-fig-0017" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 17 At least one adverse event of hypotension by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 18 At least one adverse event of headache by 24 weeks." data-id="CD004744-fig-0018" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 18 At least one adverse event of headache by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 19 At least one adverse event of anorexia by 24 weeks." data-id="CD004744-fig-0019" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 19 At least one adverse event of anorexia by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 20 At least one adverse event of bradycardia by 24 weeks." data-id="CD004744-fig-0020" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 20 At least one adverse event of bradycardia by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 21 At least one serious adverse event by 24 weeks." data-id="CD004744-fig-0021" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 21 At least one serious adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 22 At least one serious adverse event due to, or potentially due to a cerebrovascular accident by 24 weeks." data-id="CD004744-fig-0022" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia, Outcome 22 At least one serious adverse event due to, or potentially due to a cerebrovascular accident by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 1 MMSE (change from baseline at 26 weeks) ITT." data-id="CD004744-fig-0023" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 1 MMSE (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 2 FAB (change from baseline at 26 weeks) ITT." data-id="CD004744-fig-0024" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 2 FAB (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 3 Global function CDR sum of boxes (change from baseline at 26 weeks) ITT." data-id="CD004744-fig-0025" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 3 Global function CDR sum of boxes (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 4 Behavioural disturbance NPI‐12 (change from baseline at 26 weeks) ITT." data-id="CD004744-fig-0026" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 4 Behavioural disturbance NPI‐12 (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 5 IADL (change from baseline at 26 weeks) ITT." data-id="CD004744-fig-0027" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 5 IADL (change from baseline at 26 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 6 Withdrawals before end of treatment at 26 weeks." data-id="CD004744-fig-0028" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 6 Withdrawals before end of treatment at 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 7 At least one adverse event by 26 weeks." data-id="CD004744-fig-0029" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 7 At least one adverse event by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 8 At least one adverse event of recurrent stroke by 26 weeks." data-id="CD004744-fig-0030" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 8 At least one adverse event of recurrent stroke by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 9 Deaths by 26 weeks." data-id="CD004744-fig-0031" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia, Outcome 9 Deaths by 26 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 1 Clock drawing (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0032" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 1 Clock drawing (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 2 Color trails 1." data-id="CD004744-fig-0033" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 2 Color trails 1. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 3 Color trails 2." data-id="CD004744-fig-0034" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 3 Color trails 2. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 4 ADAS‐Cog (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0035" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 4 ADAS‐Cog (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 5 Behavioural disturbance NPI (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0036" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 5 Behavioural disturbance NPI (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 6 GDS depression scale (change from baseline at 24 weeks ) ITT." data-id="CD004744-fig-0037" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 6 GDS depression scale (change from baseline at 24 weeks ) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 7 ADCS‐ADL (change from baseline at 24 weeks) ITT." data-id="CD004744-fig-0038" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 7 ADCS‐ADL (change from baseline at 24 weeks) ITT. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 8 Withdrawals before end of treatment at 24 weeks." data-id="CD004744-fig-0039" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 8 Withdrawals before end of treatment at 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 9 At least one adverse event by 24 weeks." data-id="CD004744-fig-0040" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 9 At least one adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 10 At least one serious adverse event by 24 weeks." data-id="CD004744-fig-0041" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 10 At least one serious adverse event by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 11 Deaths by 24 weeks." data-id="CD004744-fig-0042" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 11 Deaths by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 12 At least one adverse event of nausea by 24 weeks." data-id="CD004744-fig-0043" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 12 At least one adverse event of nausea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 13 At least one adverse event of headache by 24 weeks." data-id="CD004744-fig-0044" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 13 At least one adverse event of headache by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 14 At least one adverse event of gastrointestinal upset by 24 weeks." data-id="CD004744-fig-0045" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 14 At least one adverse event of gastrointestinal upset by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 15 At least one adverse event of breathlessness by 24 weeks." data-id="CD004744-fig-0046" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 15 At least one adverse event of breathlessness by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 16 At least one adverse event of diarrhoea by 24 weeks." data-id="CD004744-fig-0047" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 16 At least one adverse event of diarrhoea by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 17 At least one adverse event of dizziness by 24 weeks." data-id="CD004744-fig-0048" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 17 At least one adverse event of dizziness by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 18 At least one adverse event of vomiting by 24 weeks." data-id="CD004744-fig-0049" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 18 At least one adverse event of vomiting by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 19 At least one adverse event of chest pain by 24 weeks." data-id="CD004744-fig-0050" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 19 At least one adverse event of chest pain by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD004744-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/urn:x-wiley:14651858:media:CD004744:CD004744-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_t/tCD004744-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 20 At least one adverse event of accidental fall by 24 weeks." data-id="CD004744-fig-0051" src="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND, Outcome 20 At least one adverse event of accidental fall by 24 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/media/CDSR/CD004744/image_n/nCD004744-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="comparison" data-id="CD004744-tbl-0001"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 VaDAS (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MMSE (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 ADAS‐Cog (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 ADCS‐CGIC 24 weeks ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 GDS global deterioration scale (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Behavioural disturbance NPI‐12 (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 ADCS‐ADL (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Withdrawals due to adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Deaths by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 At least one adverse event of nausea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 At least one adverse event of vomiting by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 At least one adverse event of diarrhoea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 At least one adverse event of dizziness by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 At least one adverse event of a fall by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 At least one adverse event of hypertension by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 At least one adverse event of hypotension by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 At least one adverse event of headache by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 At least one adverse event of anorexia by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 At least one adverse event of bradycardia by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 At least one serious adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 At least one serious adverse event due to, or potentially due to a cerebrovascular accident by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Rivastigmine (3‐12 mg/day) vs placebo for probable vascular dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004744-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 MMSE (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 FAB (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global function CDR sum of boxes (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Behavioural disturbance NPI‐12 (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 IADL (change from baseline at 26 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Withdrawals before end of treatment at 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 At least one adverse event by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 At least one adverse event of recurrent stroke by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Deaths by 26 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rivastigmine (6 mg/day) vs placebo for subcortical vascular dementia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD004744-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clock drawing (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.4 [‐1.58, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Color trails 1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.7 [‐20.16, 37.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Color trails 2 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 ADAS‐Cog (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Behavioural disturbance NPI (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 GDS depression scale (change from baseline at 24 weeks ) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 ADCS‐ADL (change from baseline at 24 weeks) ITT <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals before end of treatment at 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 At least one adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 At least one serious adverse event by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Deaths by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 At least one adverse event of nausea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 At least one adverse event of headache by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 At least one adverse event of gastrointestinal upset by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 At least one adverse event of breathlessness by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 At least one adverse event of diarrhoea by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 At least one adverse event of dizziness by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 At least one adverse event of vomiting by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 At least one adverse event of chest pain by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 At least one adverse event of accidental fall by 24 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Rivastigmine (3‐9 mg/day) vs placebo for MCI and CIND</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD004744.pub3/references#CD004744-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD004744.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD004744-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fr#CD004744-note-0001">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004744\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004744\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004744\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD004744\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD004744\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=OeRCveEI&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004744.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD004744.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD004744.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD004744.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD004744.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740720426662"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004744.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740720426666"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD004744.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e00e59ec59365',t:'MTc0MDcyMDQyNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 